Pharmaceutical Companies

Novo Nordisk Eli Lilly Pfizer AstraZeneca Market Strategies Lobbying Johnson & Johnson Market Competition Market Dynamics Moderna

FDA Grants Fast Track to Palvella’s QTORIN Rapamycin for Angiokeratomas

The move positions Palvella for faster FDA engagement on a 2026 Phase 2 study targeting a bleeding skin disorder with no approved therapies.

Mexico Bars Noncompliant Drug Suppliers From Next Medicine Tender

Trump’s 1,000% Drug Price Claim Draws Ridicule After Fox Interview

White House Sets Sept. 29 Deadline in Best-Price Drive as Tariff Threats Jolt Pharma

Trump Vows 1,400%–1,500% Drug Price Cuts, Threatens Tariffs Up to 250% Before Sept. 29 Deadline

Alembic Pharma Secures USFDA Approval for Liposomal Doxorubicin ANDA

Trump Administration Begins Enforcing Prescription Drug Price Controls

Trump Orders U.S. Drug Prices Tied to Lowest OECD Rates, Sparking Concerns Over Global Impact

Over 100 Women in England Secure Compensation for Vaginal Mesh Complications

Surge in GLP-1 Drugs for Weight Loss Sparks Concerns Over Diabetes Treatment

Ozempic Shows Promise Beyond Diabetes Treatment

Zealand Pharma's Petrelintide Shows Promising Results in Early Weight Loss Trial

Cencora Data Breach Exposes Sensitive Medical Information of US Patients

US House Advances Bill Targeting Chinese Biotech Firms

First US Lawsuit Filed Against AstraZeneca by Vaccine Trial Participant

Bernie Sanders Targets Novo Nordisk Over High U.S. Drug Prices

Eli Lilly Faces Zepbound Shortage, Impacting Weight Loss and Diabetes Patients

Moderna's Cancer Vaccine Shows Promising Results in Trial with Merck's Keytruda

FDA Approves Merck's Winrevair for Rare Lung Disease

Corcept Therapeutics Executives Acquire Stock Options